NCT02535104View on ClinicalTrials.gov

Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Condylomata AcuminataPapillomavirus InfectionsSexually Transmitted Diseases
Interventions
DRUG

Ranpirnase

Topical application by subject

DRUG

Vehicle

Vehicle control

Trial Locations (1)

Unknown

IDH, Cochabamba

All Listed Sponsors
lead

Tamir Biotechnology, Inc.

INDUSTRY

NCT02535104 - Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV) | Biotech Hunter | Biotech Hunter